These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 3126591

  • 1. Intravesical chemotherapy: how effective is it?
    Heney NM.
    Urology; 1988 Mar; 31(3 Suppl):17-9. PubMed ID: 3126591
    [Abstract] [Full Text] [Related]

  • 2. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS, Jordan AM, Murphy WM.
    Prog Clin Biol Res; 1989 Mar; 310():215-36. PubMed ID: 2505268
    [Abstract] [Full Text] [Related]

  • 3. Introduction and overview of intravesical therapy for superficial bladder cancer.
    Soloway MS.
    Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
    [Abstract] [Full Text] [Related]

  • 4. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intravesical chemotherapy.
    Prout GR.
    Prog Clin Biol Res; 1984 Feb; 162B():125-50. PubMed ID: 6438639
    [No Abstract] [Full Text] [Related]

  • 7. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
    Huben RP.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
    [Abstract] [Full Text] [Related]

  • 8. Treatment modalities in superficial bladder cancer.
    Irwin R, Zincke H, Droller MJ, Prout GR, Soloway MS.
    Semin Urol; 1989 Feb; 7(1 Suppl 1):1-12. PubMed ID: 2499916
    [No Abstract] [Full Text] [Related]

  • 9. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P.
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial.
    DeBruyne FM, van der Meijden AP, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg JJ.
    Urology; 1988 Mar; 31(3 Suppl):20-5. PubMed ID: 3279698
    [Abstract] [Full Text] [Related]

  • 15. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H.
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [Abstract] [Full Text] [Related]

  • 16. [Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation].
    Wang SH.
    Zhonghua Wai Ke Za Zhi; 1992 Jul; 30(7):410-2, 443-4. PubMed ID: 1301342
    [Abstract] [Full Text] [Related]

  • 17. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H.
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [Abstract] [Full Text] [Related]

  • 18. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, Shinohara N, Shinka T, Tachibana M, Naito S, Hirao Y, BCG Tokyo 172 Strain Study Group.
    Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576
    [Abstract] [Full Text] [Related]

  • 19. Intravesical therapy for superficial bladder cancer.
    Baselli EC, Greenberg RE.
    Oncology (Williston Park); 2000 May; 14(5):719-29; discussion 729-31, 734, 737. PubMed ID: 10853462
    [Abstract] [Full Text] [Related]

  • 20. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M, McGarry R, Kupelnick B.
    Anticancer Res; 2001 May; 21(1B):765-9. PubMed ID: 11299841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.